Fuchs at Rodney Parade ahead of his home debut as Newport County manager Rob Tanner/The Athletic Ten years ago, almost to the exact day, Christian Fuchs laid on the assist for Jamie Vardy’s historic ...
Property tycoon Michael Fuchs is facing a jail term after a London judge, overseeing a £37.5 million ($49.6 million) divorce award, ruled he was in contempt of court for breaching orders over the sale ...
Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma is paying $12 ...
HENDERSONVILLE — A week ago, Jack Fuchs was enjoying what he figured would be a nice autumn getaway. The Beech senior offensive lineman and Penn State football commitment went to Pennsylvania for a ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Two days before his contract was set to expire, Interim President Kent Fuchs decided to stay with the Gators a little while longer. UF spokesperson Cynthia Roldán Hernández confirmed Fuchs will remain ...
Jack Fuchs, a top football prospect in Tennessee, recently committed to Penn State. His father, Scott Fuchs, is an assistant offensive line coach for the Tennessee Titans. Beech football standout Jack ...
The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three ...
Physical activity and rehabilitation are key components of Duchenne muscular dystrophy treatment, despite recent drug therapy advances. "Rehabilitation care and rehabilitation teams with experience ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying therapies using gene replacement, antisense oligonucleotides, and gene transfer ...
Panelists discuss how data from MDA 2025 demonstrate that delandistrogene moxeparvovec (gene therapy for DMD) shows statistically significant improvements in motor function outcomes including North ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback